Skip to content
DataLookout
Menu

DMECNCT05072262

DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)

StatusUnknown
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Nov 2022); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2022 to Nov 25, 2022
    • Study sites: 0 to 1
    v3
  3. Notable Primary completion date: Jun 2023 to Jun 2024
    • Start date: Oct 2021 to May 2022
    • Study completion date: Oct 2025 to Oct 2026
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Central macular thickness after 4 weeks
Timeframe: 4 weeks after surgery
Cystoid macular edema (CME) after 4 weeks
Timeframe: 4 weeks after surgery

Secondary (7)

Intraocular inflammation
Intraocular pressure
Visual outcome
Corneal endothelial status
Patient reported outcome measure (PROM)
Show 2 moreShow less
Central macular thickness (CMT)
Cystoid macular edema (CME)

Arms and interventions

Control (dexamethasone only)Active comparator

Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery

Study group (NSAIDs and dexamethasone)Experimental

Topical nepafenac (Nevanac) 3 mg/ml and dexamethasone 1 mg/ml (Spersadex) started the day after surgery.

Drugs: Nepafenac Ophthalmic, Dexamethasone Ophthalmic

Sites

1 site in 1 country

  • Department of Ophthalmology, Oslo University HospitalOslo, Norway